InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.480
-0.080 (-5.13%)
At close: Apr 24, 2026, 4:00 PM EDT
1.520
+0.040 (2.70%)
After-hours: Apr 24, 2026, 7:20 PM EDT
InflaRx Revenue
In the year 2025, InflaRx had annual revenue of 29.33K EUR, down -82.31%. InflaRx had revenue of -33.93K in the quarter ending December 31, 2025.
Revenue (ttm)
29.33K EUR
Revenue Growth
-82.31%
P/S Ratio
3,106.84
Revenue / Employee
451 EUR
Employees
65
Market Cap
106.99M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sangamo Therapeutics | 39.55M |
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Coya Therapeutics | 7.95M |
| Cibus | 3.64M |
| Coeptis Therapeutics Holdings | 1.36M |
| Genelux | 8.00K |
IFRX News
- 16 days ago - InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor - GlobeNewsWire
- 25 days ago - InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 26 days ago - InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 5 weeks ago - InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - InflaRx to Report Full Year 2025 Results on March 19, 2026 - GlobeNewsWire
- 6 weeks ago - InflaRx Transcript: Leerink Global Healthcare Conference 2026 - Transcripts